A biotech startup aiming to fundamentally alter the course of challenging neurological conditions has just closed a significant funding round. Latus Bio, which develops novel gene therapies for CNS disorders like CLN2 (Batten Disease) and Huntington’s Disease, announced it has raised $97.0M in Series A capital.
The company's approach centers on revolutionary AAV capsids designed for unprecedented potency and specificity, building on the foundational work of Professor Beverly Davidson from the Children's Hospital of Philadelphia. Latus Bio plans to enter clinical trials by late 2025.















